Literature DB >> 7610843

Neurotological evaluation of Harada's disease.

T Tahara1, T Sekitani.   

Abstract

We have had 30 patients with Harada's disease at our clinic from 1980 to 1993 and their neurotological findings were retrospectively reviewed. There were 12 males and 18 females, whose ages ranged from 15-years to 67-years. Preceding symptoms such as headache or common cold were observed in 50% of the patients. Pleocytosis of the cerebrospinal fluid was found in 89% of the patients. Subjective cochlear and/or vestibular symptoms were noted in 60% of the patients. In 43 of the 50 ears, sensorineural hearing loss (< 40 dB) was observed. In 77% of the patients, vestibular function tests gave abnormal results. On the basis of our findings, it was suggested that Harada's disease with vertiginous and cochlear symptoms could be classified as follows: cochlear type, peripheral vestibular type, cochleovestibular type, central type, and 'unclassified', based on the neurotological results.

Entities:  

Mesh:

Year:  1995        PMID: 7610843     DOI: 10.3109/00016489509121882

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  4 in total

Review 1.  Vertigo and autoimmunity.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-10-16       Impact factor: 2.503

2.  Vogt-Koyanagi-Harada disease presenting as optic neuritis.

Authors:  Ranjan Rajendram; Monica Evans; Rahul N Khurana; Julie H Tsai; Narsing A Rao
Journal:  Int Ophthalmol       Date:  2007-04-17       Impact factor: 2.029

Review 3.  Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment.

Authors:  Laura Girasoli; Diego Cazzador; Roberto Padoan; Ennio Nardello; Mara Felicetti; Elisabetta Zanoletti; Franco Schiavon; Roberto Bovo
Journal:  J Immunol Res       Date:  2018-09-26       Impact factor: 4.818

Review 4.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.